Peptides for Eye Health: Corneal Healing, Dry Eye, and Beyond

The eye is one of the most peptide-rich tissues in the body. Tear fluid contains dozens of bioactive peptides, and the cornea undergoes constant repair cycling that relies on endogenous growth factors and signaling molecules. This overlap between natural ocular biology and peptide therapeutics has made eye health one of the more scientifically grounded applications in peptide research — though the gap between laboratory findings and clinical availability remains wide.

Thymosin beta-4 and corneal repair

Thymosin beta-4 (TB-4) is the standout peptide in ophthalmic research. This 43-amino-acid peptide is naturally present in human tears and plays a central role in corneal wound healing. Its mechanism in the eye is well-characterized:

Anti-inflammatory action. TB-4 reduces the inflammatory cascade that follows corneal injury, limiting the neutrophil infiltration and cytokine release that can cause secondary tissue damage. In the cornea, where transparency depends on precise structural organization, controlling inflammation is critical — excessive inflammatory response causes scarring and opacity.

Epithelial cell migration. TB-4 promotes the migration and spreading of corneal epithelial cells across the wound bed. This is mediated through its interaction with actin, the cytoskeletal protein that drives cell movement. The corneal epithelium regenerates every 7-10 days under normal conditions, and TB-4 accelerates this process in injured tissue.

Anti-scarring properties. Perhaps most relevant clinically, TB-4 appears to reduce corneal scarring by modulating the transformation of keratocytes into myofibroblasts — the cells responsible for producing the disorganized collagen that causes corneal opacity.

The clinical evidence for TB-4 in eyes

This is where ophthalmic peptide research distinguishes itself from many other peptide applications: there are actual clinical trials. RegeneRx Biopharmaceuticals developed RGN-259, a sterile eye drop formulation of thymosin beta-4 (0.1%), and advanced it through Phase 2 clinical trials for dry eye syndrome and neurotrophic keratopathy.

The dry eye trial results showed statistically significant improvements in corneal fluorescein staining (a measure of surface damage), symptom scores, and tear film quality compared to vehicle control. The neurotrophic keratopathy data — a condition where corneal nerves are damaged, preventing normal healing — showed complete corneal healing in patients who had failed conventional treatments.

These are not animal-only findings. This is human clinical data with proper controls, and it represents some of the strongest clinical evidence for any non-cosmetic peptide application.

GHK-Cu for ocular surface health

GHK-Cu's role in eye health is less directly studied than TB-4, but its mechanisms are relevant. The copper peptide complex promotes tissue remodeling, collagen organization, and stem cell recruitment — all processes active in corneal and conjunctival repair.

Preclinical studies have explored GHK-Cu's effects on corneal fibroblasts, showing increased proliferation and organized extracellular matrix deposition. The anti-inflammatory gene expression profile documented in skin studies (upregulation of anti-inflammatory pathways, suppression of destructive metalloproteinases) would theoretically benefit ocular surface inflammation.

However, ophthalmic formulation of GHK-Cu presents challenges. The copper ion must remain complexed to the peptide for biological activity, and tear fluid chemistry (pH, ionic strength, protein content) affects complex stability. No clinical trials of GHK-Cu specifically for ophthalmic use have been published. The evidence here is mechanistic extrapolation from skin and wound healing data, not direct ocular evidence.

Dry eye disease: the peptide opportunity

Dry eye disease affects an estimated 16 million diagnosed Americans and likely many more undiagnosed. Current treatments — artificial tears, cyclosporine (Restasis), lifitegrast (Xiidra) — manage symptoms or modulate inflammation but do not directly promote corneal surface healing. This is the therapeutic gap that peptides like TB-4 address: rather than just suppressing inflammation, they actively support the repair of damaged ocular surface tissue.

The distinction matters clinically. Many dry eye patients have persistent corneal epithelial defects that contribute to symptoms even when inflammation is controlled. A treatment that accelerates epithelial healing would complement existing anti-inflammatory approaches.

BPC-157 and the eye: limited data

BPC-157 is sometimes discussed for ocular applications based on its broad tissue-healing profile. However, direct evidence for BPC-157 in eye tissue is extremely thin. A small number of preclinical studies have examined BPC-157's effects on corneal injuries in animal models, with some positive findings for healing acceleration. But the data is nowhere near the depth available for TB-4 in ophthalmic contexts.

The gastric peptide's mechanism — involving VEGF-mediated angiogenesis — actually raises concerns in the corneal context. The cornea is normally avascular, and unwanted blood vessel growth (corneal neovascularization) is a serious complication that impairs vision. Any pro-angiogenic compound requires careful evaluation before ophthalmic application.

Practical considerations

Ophthalmic peptide use differs fundamentally from other peptide applications:

Formulation matters enormously. The eye's tear film, blink reflex, and nasolacrimal drainage system clear topically applied compounds within minutes. Effective ophthalmic peptides require specific formulation — viscosity agents, preservative-free packaging, appropriate pH buffering — to achieve therapeutic contact time.

Sterility is non-negotiable. The eye is uniquely vulnerable to infection. Any peptide preparation used in or near the eye must meet ophthalmic sterility standards. Reconstituted research peptides intended for subcutaneous injection should never be applied to the eyes.

Regulatory status. As of 2026, no peptide eye drop is FDA-approved, though RGN-259 has advanced through clinical trials. Practitioners in some regions compound thymosin beta-4 eye drops for off-label use.

The evidence hierarchy

• Thymosin beta-4 (topical, ophthalmic): Phase 2 clinical data for dry eye and neurotrophic keratopathy. Strongest evidence of any peptide in ophthalmology. Confidence: moderate-to-high.
• GHK-Cu (topical, ophthalmic): Mechanistic rationale from skin data, limited direct ocular evidence. Confidence: low.
• BPC-157 (ophthalmic): Minimal direct data, theoretical angiogenesis concerns. Confidence: very low.

The eye represents one of the more promising frontiers in therapeutic peptide development — precisely because the biology is well-understood and the clinical trials have actually been conducted. Thymosin beta-4 eye drops may eventually become a standard treatment for corneal healing disorders. But that clinical pathway is still in progress.

FAQ

Can peptide eye drops help with dry eye syndrome?

Thymosin Beta-4 (as RGN-259 eye drops) has Phase 2 clinical trial data specifically for dry eye disease, showing improvements in ocular surface staining scores and symptom relief. This is the only peptide with controlled clinical evidence in ophthalmology. Other peptides marketed for dry eye (GHK-Cu eye serums, etc.) lack direct ocular clinical data — their claims are extrapolated from skin and wound healing studies, which is not a reliable basis for ophthalmic use.

Is it safe to put peptides in your eyes?

Only ophthalmic-grade preparations formulated specifically for ocular use should ever contact the eye. Research peptides reconstituted for subcutaneous injection contain bacteriostatic water with benzyl alcohol preservative, which is irritating and potentially harmful to ocular tissues. Any ocular peptide product must be preservative-free, sterile, pH-buffered (6.5-7.4), and isotonic. Compounded thymosin beta-4 eye drops prepared by compounding pharmacies to ophthalmic standards are the only peptide eye preparations with any clinical basis.

Can BPC-157 help with eye injuries?

BPC-157 has not been studied specifically for ocular applications, and its pro-angiogenic mechanism (VEGF upregulation) is actually concerning in the eye context. The cornea is normally avascular, and unwanted blood vessel growth (corneal neovascularization) is a vision-threatening complication. Until ocular-specific studies establish safety, BPC-157 should not be used in or around the eye. For corneal healing, thymosin beta-4 has a more appropriate mechanism and actual clinical trial data.

What peptides help with macular degeneration?

No peptide has established clinical evidence for treating age-related macular degeneration (AMD). The current standard of care for wet AMD involves anti-VEGF injections (ranibizumab, aflibercept) — these are biologic agents, not peptides in the research peptide sense. SS-31 (elamipretide) is being investigated for mitochondrial dysfunction in retinal diseases, but this research is early-stage. Macular degeneration requires ophthalmologist management with proven anti-VEGF therapies.